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Objective:  this  triple-masked  controlled  trial  aimed  to  assess  the  effects  of  vitamin  D  supple-
mentation on  insulin  resistance  and  cardiometabolic  risk  factors  in  obese  children  and
adolescents.
Methods:  the  study  comprised  50  participants,  aged  10  to16  years,  who  were  randomly  assigned
into two  groups  of  equal  number.  In  this  12-week  trial,  one  group  received  oral  vitamin  D
(300,000  IU)  and  the  other  group  received  placebo.  Cardiometabolic  risk  factors,  insulin  resis-
tance,  and  a  continuous  value  of  metabolic  syndrome  (cMetS)  were  determined.  Statistical
analysis  was  conducted  after  adjustment  for  covariate  interactions.
Results:  overall,  21  patients  in  the  vitamin  D  group  and  22  in  the  placebo  group  completed  the
trial.  No  signiﬁcant  difference  was  observed  in  the  baseline  characteristics  of  the  two  groups.
After  the  trial,  in  the  vitamin  D  group,  serum  insulin  and  triglyceride  concentrations,  as  well  as
HOM  -IR  and  C-MetS  decreased  signiﬁcantly,  both  when  compared  with  the  baseline  and  with
the  placebo  group.  No  signiﬁcant  difference  was  observed  when  comparing  total  cholesterol,
LDL-C,  HDL-C,  fasting  blood  glucose,  and  blood  pressure.
Conclusion:  the  present  ﬁndings  support  the  favorable  effects  of  vitamin  D  supplementation
on reducing  insulin  resistance  and  cardiometabolic  risk  factors  in  obese  children.
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Resistência  à  insulina;
Crianc¸as e
adolescentes
Efeitos  da  suplementac¸ão  de  vitamina  D  sobre  a  resistência  à  insulina  e  fatores  de
risco  cardiometabólico  em  crianc¸as  com  síndrome  metabólica:  ensaio  clínico
triplo-cego  controlado
Resumo
Objetivo:  este  ensaio  clínico  triplo-cego  controlado  visa  investigar  os  efeitos  da  suplementac¸ão
de vitamina  D  sobre  a  resistência  à  insulina  e  os  fatores  de  risco  cardiometabólico  em  crianc¸as
e adolescentes  obesos.
Métodos: o  estudo  contou  com  50  participantes  com  idade  entre  10  e  16  anos,  aleatoriamente
divididos em  dois  grupos  de  igual  número  de  participantes.  Neste  ensaio  clínico  de  12  semanas,
um  grupo  recebeu  vitamina  D  via  oral  (300000  IU)  e  o  outro  grupo  recebeu  placebo.  Foram
determinados fatores  de  risco  cardiometabólico,  resistência  à  insulina  e  valor  contínuo  da  sín-
drome  metabólica  (cMetS).  A  análise  estatística  foi  conduzida  após  o  ajuste  das  interac¸ões
covariáveis.
Resultados:  no  todo,  21  pacientes  no  grupo  vitamina  D  e  22  no  grupo  placebo  concluíram  o
ensaio clínico.  Nenhuma  diferenc¸a signiﬁcativa  foi  encontrada  nas  características  de  base  dos
dois  grupos  estudados.  Após  o  ensaio  clinico,  no  grupo  vitamina  D,  as  concentrac¸ões  séricas  de
insulina  e  triglicerídeos,  bem  como  HOMA-RI  e  cMetS  caíram  signiﬁcativamente  em  comparac¸ão
ao início  do  estudo;  e  também  em  comparac¸ão  ao  grupo  placebo.  Nenhuma  diferenc¸a signi-
ﬁcativa  foi  vista  ao  comparar  o  colesterol  total,  LDL-C,  HDL-C,  glicemia  de  jejum  e  pressão
sanguínea.
Conclusão:  nossas  conclusões  indicam  efeitos  favoráveis  da  suplementac¸ão  de  vitamina  D  sobre
a  reduc¸ão  da  resistência  à  insulina  e  de  fatores  de  risco  cardiometabólico  em  crianc¸as  obesas.
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Most  chronic  non-communicable  diseases  and  their  risk  fac-
tors begin  early  in  life.  Therefore,  in  recent  years,  much
attention has  been  focused  on  the  primary  prevention  of
diseases from  childhood.  The  long-term  effects  of  child-
hood obesity,  such  as  cardiometabolic  risk  factors  including
metabolic syndrome  (MetS)  are  of  special  concern.1
In  this  context,  prevention  and  early  control  of  risk  fac-
tors are  of  crucial  importance.  MetS  is  an  underlying  cause
of most  chronic  diseases,  and  insulin  resistance  is  suggested
to have  an  underlying  role  in  the  development  of  MetS.  Such
disorders are  not  limited  to  adults  and  to  industrialized
countries, rather,  they  are  becoming  as  an  important
health problem  for  children  and  adolescents  in  several
countries.2 The  authors’  previous  national  studies  reported
a high  prevalence  of  MetS  and  cardiometabolic  risk  factors
in Iranian  children  and  adolescents.3,4 In  recent  years,
signiﬁcant relationships  have  been  documented  between
vitamin D  deﬁciency  and  various  non-communicable  dis-
eases, notably  cardiovascular  diseases  and  diabetes,  as  well
as with  their  predisposing  factors,  such  as  MetS  and  insulin
resistance. Vitamin  D  has  an  important  role  in  glucose
and insulin  metabolism.5 It  affects  pancreatic  islet  cells
through its  receptors  and  may  increase  insulin  secretion.
Vitamin D  deﬁciency  leads  to  elevated  PTH  levels,  and  in
turn to  decreased  insulin  sensitivity.  Moreover,  vitamin  D
has anti-inﬂammatory  and  immune  modulating  effects,
and might  lead  to  a  decrease  in  insulin  resistance  and  an
increase in  insulin  secretion  by  modulating  the  immune
system.6 Low  serum  levels  of  vitamin  D  are  suggested  to  be
associated with  insulin  resistance  and  cardiometabolic  risk
factors even  in  young  age.  Thus,  different  doses  of  vitamin
P
T
c supplementation  are  proposed  for  prevention  of  these
isk factors  in  healthy  children  and  adolescents.7 However,
hether vitamin  D  supplementation  would  improve  insulin
ensitivity and  metabolic  risk  factors  in  the  pediatric
ge group  is  controversial.  The  current  study  aimed  to
nvestigate the  effects  of  oral  vitamin  D  supplementation
n insulin  resistance  and  cardiometabolic  risk  factors  in
bese children  and  adolescents.
ethods
his  triple-masked  controlled  trial  was  conducted  in  2012
n Isfahan,  Iran,  and  was  approved  by  the  Research  Coun-
il and  the  Ethics  Committee  of  the  Isfahan  University
f Medical  Sciences.  The  trial  was  registered  with  the
ode IRCT201110271434N5  in  the  Iranian  Registry  of  Clinical
rials, which  is  a primary  registry  in  the  World  Health  Orga-
ization (WHO)  Registry  Network.  This  trial  was  conducted
n accordance  with  the  principles  of  the  Helsinki  Declara-
ion. An  informed  consent  was  obtained  from  parents  and
ral assent  from  participants.  Considering  an    error  of  0.05
nd a    error  of  20%,  and  also  considering  the  effect  of  vita-
in D  supplementation  on  insulin  sensitivity  in  a  previous
rial among  obese  individuals,8 the  sample  size  was  calcu-
ated as  20  in  the  intervention  group,  and  20  in  the  placebo
roup. Due  to  possible  attrition  during  the  trial,  the  sample
ize was  increased  to  25  in  each  group.articipants
he  study  was  conducted  among  children  and  adoles-





































































































niversity  of  Medical  Sciences.  Eligibility  criteria  were  age
etween 10  years  and  16  years,  body  mass  index  equal  to
r greater  than  three  Z-scores,9 and  presence  of  MetS.10,11
xclusion  criteria  were  any  medication  or  supplementation
se and  any  chronic  disease.  Obese  children  and  adoles-
ents were  invited  to  participate,  and  if  after  receiving
heir laboratory  data,  they  fulﬁlled  the  criteria  of  MetS,  they
ere recruited  to  the  trial.  Sampling  continued  until  reach-
ng the  necessary  number  of  participants  for  the  trial.  The
emographic variables  were  determined  through  a  validated
uestionnaire.12
hysical  examination  and  laboratory  tests
nthropometric  indexes,  as  well  as  systolic  (SBP)  and  dia-
tolic (DBP)  blood  pressure  were  measured  by  trained  nurses
ccording to  standard  protocols,  using  calibrated  instru-
ents. Fasting  venous  blood  sample  was  examined  for
asting plasma  glucose  (FPG)  and  lipid  proﬁle  by  autoan-
lyzer with  standard  kits  (Pars  Azmoun  -  Tehran,  Iran).
erum concentration  of  25-hydroxy  vitamin  D  (25(OH)D)  was
nalyzed using  the  chemiluminescent  immunnoassay  (CLIA)
ethod (25  OH  VitD  CLIA  kit,  Diasorin  -  Stillwater,  MN,United
tates); the  kit’s  expected  range  is  4  to  150  ng/mL.  The  low-
st reportable  value  was  4.0  ng/mL,  which  is  based  on  an
nter-assay precision  that  approximates  20%  CV  (functional
ensitivity).
Plasma insulin  was  measured  by  radioimmunoassay  (RIA)
LINCO Research  Inc),  which  is  100%  speciﬁc  for  human
nsulin with  less  than  0.2%  cross-reactivity  with  human  proin-
ulin and  no  cross  reactivity  with  c-peptide  or  insulin-like
rowth factor.  Insulin  resistance  (IR)  was  calculated  on  the
asis of  the  homeostasis  model  assessment  of  IR  (HOMA-IR),
sing the  following  formula:
[HOMA-IR  =  (fasting  insulin  (mU/L)  x fasting  glucose
mmol/L)/22.5].
eﬁnition  of  cardiometabolic  risk  factors  and  MetS
ardiometabolic  risk  factors  were  deﬁned  according  to  the
atest cut-off  points  provided  by  the  National  Heart,  Lung,
nd Blood  Institute  for  the  pediatric  age  group.13 As  there
s no  universal  deﬁnition  of  MetS  in  the  pediatric  age  group,
 continuous  value  of  MetS  (cMetS)  was  used,  as  recom-
ended by  the  American  Diabetes  Association  and  the
uropean Association  for  the  Study  of  Diabetes  for  children
nd adolescents.9 The  cMetS  score  was  derived  by  ﬁrst  stan-
ardizing the  residuals  for  waist  circumference  (WC),  high
ensity lipoprotein-cholesterol  (HDL-C),  triglycerides  (TG),
asting blood  glucose  (FBG),  and  mean  arterial  blood  pres-
ure (MAP)  by  regressing  them  based  on  age  and  gender
o account  for  age-  and  gender-related  differences.  MAP
as calculated  using  the  following  equation:  MAP  =  [(SBP-
BP)/3] +  DBP.  Since  the  standardized  HDL-C  is  inversely
elated to  the  MetS  risk,  it  was  multiplied  by  -1.  The  cMetS
core was  calculated  as  the  sum  of  the  standardized  resid-
als (Z-scores)  for  the  individual  variables.  A  higher  cMetS
core indicates  a  less  favorable  metabolic  proﬁle.  The  cMetS
core has  been  previously  validated  by  the  authors  in  Iranian
hildren and  adolescents.11
c
b
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edication  and  placebo
he  Zahravi  Pharmaceutical  company,  which  manufactures
oft gel  capsules  containing  50,000  IU  of  vitamin  D3,  col-
aborated with  the  trial  in  preparing  placebo.  They  were
dentical in  appearance  with  the  vitamin  D  capsules,  and
oth were  tasteless  and  odorless.
tudy  intervention
he  trial  statistician  generated  a  randomization  list  using
tata, version  9  (College  Station  -  TX,  United  States).  Par-
icipants were  randomly  assigned  to  two  groups  of  equal
umber. All  trial  staff,  participants,  and  the  statistician
ere masked  to  treatment  allocation  throughout  the  study.
One  group  received  300,000  IU  (one  capsule  per  week)
f vitamin  D3,14 and  the  other  group  received  placebo.  Both
roups received  similar  recommendations  for  healthy  eating
nd reduction  of  sedentary  activities.
Compliance  with  consumption  of  medication  or  placebo
as assessed  by  weekly  phone  follow-up  and  monthly  visits
n the  clinic.  Twelve  weeks  after  randomization,  all  baseline
linical and  laboratory  examinations  were  repeated  in  both
roups. The  entire  program  was  offered  free  of  charge.
tatistical  analysis
ata  analyses  were  performed  using  the  Statistical  Package
or Social  Sciences  (SPSS),  version  20.0  (SPSS  Inc.  -  Chicago,
L, United  States).  The  normality  of  the  distribution  of  varia-
les was  conﬁrmed  by  the  Kolmogorov--Smirnov  test.  The
ntention to  treat  principle  was  used  throughout  the  anal-
sis. Student’s  t-test  was  used  to  compare  the  mean  of
uantitative variables  before  and  after  the  intervention.
he comparison  of  pre-and-post-intervention  within  each
roup was  calculated  by  paired  t-test.  Analysis  of  covari-
nce were  used  to  adjust  results  for  the  dependent  variables
easured before  and  after  the  trial  for  treatment  covariate
nteractions. All  values  were  reported  as  mean  ±  SD.  ptime,
group and  ptime × group were  calculated  for  all  variables.
esults
he  study  ﬂow  chart  shows  the  screening,  randomization,
nd follow-up  of  the  participants  (Fig.  1).  Overall,  21
atients in  the  vitamin  D  group  and  22  in  the  placebo  group
ompleted the  trial.  No  signiﬁcant  difference  was  observed
n the  baseline  characteristics  of  the  two  groups  studied.  The
ntra-group and  inter-group  differences  in  variables  before
nd after  the  trial  are  presented  in  Table  1.
At  baseline,  the  mean  concentrations  of  serum  25(OH)D
ere not  signiﬁcantly  different  between  the  groups  studied;
fter the  trial,  the  group  receiving  vitamin  D  had  signiﬁcant
ntra-group (p  =  0.01)  and  inter-group  (p  =  0.02)  increases.
his was  conﬁrmatory  evidence  of  the  compliance  of  partic-
pants in  taking  vitamin  D  capsules.After  the  trial,  in  the  vitamin  D  group,  serum  TG
oncentration decreased  signiﬁcantly  compared  with  the
aseline (p  =  0.04);  and  also  compared  with  the  placebo
roup (p  =  0.02).  A  signiﬁcant  decrease  was  observed  in
Effects  of  vitamin  D  supplementation  on  insulin  resistance  and  cardiometabolic  risk  31
Table  1  Characteristics  of  participants  at  baseline  and  after  the  trial.
Variables  Vitamin  D  Groupa (n=21)  Placebo  Groupb (n=22)  p  overallc ptimed pgroupe p time  ×  groupf ptime  ×  ageg
BMI  (kg/m2)
Before  28.08  ±  1.06  27.81  ±  1.04  0.61  0.42  0.56  0.41  0.55
After  27.91  ±  1.04  27.24  ±  1.01  0.68
ph 0.51 0.48  -
WC (cm)
Before  90.08  ±  6.01 90.03 ±  5.04 0.64 0.52  0.46  0.61  0.45
After  89.02  ±  5.04 89.07 ±  5.01 0.58
ph 0.61  0.58  -
WHtR
Before 06/01  ±  0/02  06.03  ±  0.04  0.61  0.47  0.51  0.64  0.51
After  06.01  ±  0.01  06.02  ±  0.05
ph 0.51  0.48  -
25(OH)D (ng/mL)
Before 18.27  ±  2.04  17.91  ±  2.27  0.48  0.06  0.04  0.02  0.03
After  32.01  ±  2.14  19.07  ±  2.01  0.02
ph 0.01  0.15  -
Insulin(U/L)
Before 14.27  ±  1.32  14.19  ±  1.20  0.31  0.37  0.31  0.51  0.27
After  13.71  ±  1.58  14.07  ±  1.04  0.02
ph 0.04  0.28  -
FBG (mg/dL)
Before  94.27  ±  5.32 92.20 ±  6.21  0.48  0.61  0.41  0.52  0.47
After  90.71  ±  4.58  90.07  ±  5.64  0.21
ph 0.06  0.28  -
HOMA-IR
Before 3.21  ±  0.11  3.15  ±  0.26  0.48  0.42  0.51  0.32  0.25
After  2.81  ±  0.25  3.07  ±  0.14  0.02
ph 0.04  0.28  -
TG(mg/dL)
Before 141.21  ±  24.15  143.15  ±  23.26  0.48  0.41  0.31  0.35  0.27
After  102.81  ±  27.20  137.07  ±  25.14  0.02
ph 0.04  0.08  -
TC(mg/dL)
Before 161.50  ±  3.21  164.18  ±  5.18  0.27  0.32  0.25  0.21  0.51
After  160.18  ±  2.35  162.15  ±  4.21  0.35
P8 0.54  0.41  -
HDL-C(mg/dL)
Before 47.06  ±  4.01  48.72  ±  4.12  0.34  0.12  0.26  0.38  0.51
After  45.21  ±  3.18  44.35  ±  2.19  0.48
ph 0.45  0.46  -
LDL-C(mg/dL)
Before 97.01  ±  4.19  95.68  ±  2.87  0.58  0.76  0.861  0.57  0.51
After  93.17  ±  5.21  92.56  ±  4.12  0.67
ph 0.08  0.07  -
MAP (mmHg)
Before  134.01  ±  5.89  136.61  ±  6.08  0.53  0.76  0.81  0.58  0.52
After  131.47  ±  4.69  135.26  ±  4.52  0.07
ph 0.06  0.12  -
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Table  1  (Continued)
Variables  Vitamin  D  Groupa (n=21)  Placebo  Groupb (n=22)  p  overallc ptimed pgroupe p time  ×  groupf ptime  ×  ageg
C-MetS
Before  4.21  ±  0.89  4.36  ±  0.78  0.51  0.26  0.41  0.38  0.42
After  3.17  ±  0.61  4.01  ±  0.52  0.02
ph 0.04  0.12  -
BMI, body mass index; C-MetS, continuous metabolic syndrome; FBG, fasting blood glucose; HDL-C, high density lipoprotein-cholesterol;
HOMA-IR,  homeostasis model of assessment - insulin resistance; LDL-C, low density lipoprotein-cholesterol; MAP, mean arterial blood
pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHtR, waist to height ratio; 25(OH)D, 25-hydroxyvitamin D.
All values are presented as mean ± SD.
a 300,000 IU vitamin D3.
b Softgel capsules identical to the vitamin D3 capsules.
c p-values present comparison of baseline and end point values between two groups (computed by Student’s t-test for independent
samples).
d p-values demonstrate the effect of time (computed by analysis of the covariance).
e p-values represent the effect of grouping (computed by analysis of the covariance).
f p-values represent the time*group interaction (computed by analysis of the covariance).
g p-values represent the time*age interaction (computed by analysis 
h p-values present comparison of baseline and end point values withi
Individuals screene d for elig ibilit y
(n=354)
Ineligib le (n=28 7) 
Refused  to part icipate  (n=49) 
 Other  rea sons (n=18 ) 
Include d in  dat a anal ysis  (n =21)
Nonc ompliance (n=3 ) 
Other (n=1) 
Vitamin D (n=2 5) 
Noncomplia nce (n=1) 
Moving to another  ci ty (n =1) 
Other reasons  (n=1 ) 
Placebo (n=25) 
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iFigure  1  Study  algorithm.
erum  insulin  levels  and  HOMA-IR  in  the  vitamin  D  group
t the  end  of  the  study  in  comparison  with  the  base-
ine (p  =  0.04).  At  the  end  of  the  study,  the  serum  insulin
evels and  HOMA-IR  had  a  signiﬁcant  difference  between
he groups  (p  =  0.02  and  p  =  0.02,  respectively),  showing
mprovement in  IR  in  the  group  receiving  vitamin  D.  Com-
arison of  cMetS  at  the  baseline  and  after  the  trial  showed
igniﬁcant decrease  in  the  vitamin  D  group  when  compared
o the  placebo  group  (p  =  0.04).  However,  no  signiﬁcant  dif-
erences were  observed  when  comparing  the  serum  levels
f total  cholesterol,  LDL-C,  HDL-C,  FBG,  and  BP  at  base-
ine and  after  the  trial  both  intra-group  (p  =  0.54,  p  =  0.08,
 =  0.45,  p  =  0.06,  and  p  =  0.06,  respectively)  and  inter-group
p = 0.41,  p  =  0.07,  p  =  0.46,  p  =  0.28,  and  p  =  0.07).
iscussiono  the  best  of  the  authors’  knowledge,  the  present  study
s one  of  the  ﬁrst  of  its  kind  in  the  pediatric  age  group,




n each group (computed by Student’s t-test for paired samples).
U)  on  insulin  resistance,  MetS,  and  TG  in  obese  chil-
ren and  adolescents.  There  is  increasing  evidence  that
itamin D  deﬁciency  is  associated  with  risk  factors  of  non-
ommunicable diseases,  including  components  of  the  MetS
nd other  cardiometabolic  risk  factors  even  in  children  and
dolescents.15--17 Insulin  resistance  is  considered  as  one  of
he main  underlying  causes  of  MetS.  Some  studies  have
emonstrated an  inverse  relationship  between  vitamin  D
evels and  insulin  resistance.18,19 Inﬂammatory  cytokine  pro-
uction is  considered  to  be  one  of  the  mechanisms  of
he effect  of  vitamin  D  on  insulin  resistance;  inﬂamma-
ory cytokines  are  associated  with  both  obesity  and  insulin
esistance.20 There  is  further  evidence  of  a relationship
etween vitamin  D  metabolism  and  diabetes  mellitus.  Vita-
in D  is  involved  in  insulin  secretion  and  probably  on  its
unction, hypophysis  regulation  and  glucose  homeostasis,
hich eventually  can  lead  to  the  development  of  MetS.21 It
as been  suggested  that  low  serum  levels  of  vitamin  D  may
ncrease insulin  resistance,  and  in  turn  the  risk  of  diabetes
ellitus type  2  over  time.20
Previous  trials  on  the  effects  of  vitamin  D  on  car-
iometabolic risk  factors  and  insulin  resistance  have  been
erformed with  adults.19,22--26
The  present  results  conﬁrm  a  signiﬁcant  relationship
etween vitamin  D  deﬁciency  and  increased  blood  pressure,
G, insulin  resistance,  and  MetS.  The  ﬁndings  of  this  study
re in  agreement  with  those  of  other  clinical  trials  con-
ucted among  adults;  and  an  inverse  relationship  has  been
bserved between  serum  concentration  of  vitamin  D  and  the
isk of  MetS  and  insulin  resistance.22--24 Furthermore,  several
ross-sectional studies  presented  the  same  results.19,25,26
or  instance,  in  a  study  among  postmenopausal  women,  an
nverse relationship  was  documented  between  serum  levels
f vitamin  D  with  TG,  HDL/TG,  and  MetS,  but  the  corre-
ponding ﬁgures  were  not  signiﬁcant  for  LDL-C,  HDL-C,  and
nsulin.22Conversely,  other  studies  conducted  among  adults  did
ot document  a  signiﬁcant  association  between  vitamin  D
evels and  the  abovementioned  indexes.27,28 Likewise,  a
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ﬁnd  a  signiﬁcant  correlation  between  vitamin  D  levels  and
insulin resistance  or  MetS.29 Differences  in  the  age  groups
studied, severity  of  weight  excess,  and  cardiometabolic  risk
factors, as  well  as  the  doses  of  vitamin  D  supplementation
can explain  the  controversies  in  the  ﬁndings  of  various  stud-
ies. The  dose  and  interval  of  vitamin  D  supplementation  for
improving the  serum  vitamin  D  levels  of  children  remain
undetermined.30
Study  limitations  and  strengths
Although  some  signiﬁcant  differences  were  observed,  which
indicate that  a  sufﬁcient  number  of  subjects  were  studied,
a larger  sample  size  with  longer  period  of  follow-up  perhaps
would have  obtained  more  favorable  results.  The  strengths
of the  present  study  are  its  novelty  in  the  pediatric  age  group
and the  assessment  of  independent  association  of  vitamin  D
with the  risk  factors  studied.
Conclusion
Vitamin  D  supplementation  was  inversely  associated  with
insulin resistance  and  some  cardiometabolic  risk  factors.
Vitamin D  supplementation  may  have  beneﬁcial  effects  on
controlling some  complications  of  childhood  obesity.
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